Teva’s ProAir Digihaler FDA Approved to Monitor Asthma and COPD Treatment

Teva Pharmaceutical, based in Israel, landed the first FDA approval for a digital inhaler with built-in sensors. The ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder is indicated for people suffering from asthma & COPD as a way of preventing and treating bronchospasm, a tightening of the muscles that line the airways. The ProAir Digihaler monitors how it’s used and uploads the data to an accompanying smartphone app via Bluetooth wireless connectivity. Specifically, the device detects every time it has been use to administer treatment, as well as the inspiratory airflow during each inhalation.